Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 345

1.

Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapy.

Classen S, Kopp R, Possinger K, Weidenhagen R, Eiermann W, Wilmanns W.

Tumour Biol. 2002 Mar-Apr;23(2):70-5.

PMID:
12065844
2.

Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer.

Kopp R, Classen S, Wolf H, Gholam P, Possinger K, Wilmanns W.

Anticancer Res. 2001 Jul-Aug;21(4B):2995-3000.

PMID:
11712800
3.

Local immunotherapy of glioma patients with a combination of 2 bispecific antibody fragments and resting autologous lymphocytes: evidence for in situ t-cell activation and therapeutic efficacy.

Jung G, Brandl M, Eisner W, Fraunberger P, Reifenberger G, Schlegel U, Wiestler OD, Reulen HJ, Wilmanns W.

Int J Cancer. 2001 Jan 15;91(2):225-30.

4.

Modulation of CD95 in leukemia and lymphoma cells by retinoids.

Munker R, Koeffler P, Haas R, Wilmanns W.

Eur J Med Res. 2000 Jun 20;5(6):273-6.

PMID:
10882644
5.

Prognostic significance of increased IL-10 production in patients prior to allogeneic bone marrow transplantation.

Holler E, Roncarolo MG, Hintermeier-Knabe R, Eissner G, Ertl B, Schulz U, Knabe H, Kolb HJ, Andreesen R, Wilmanns W.

Bone Marrow Transplant. 2000 Feb;25(3):237-41.

6.

Second malignancies after Hodgkin's disease: the Munich experience.

Munker R, Grützner S, Hiller E, Aydemir U, Enne W, Dietzfelbinger H, Busch M, Haas R, Emmerich B, Schmidt M, Dühmke E, Hölzel D, Wilmanns W.

Ann Hematol. 1999 Dec;78(12):544-54.

PMID:
10647878
7.

Drug-induced apoptosis in chronic lymphocytic leukemia.

Stoetzer OJ, Pogrebniak A, Scholz M, Pelka-Fleischer R, Gullis E, Darsow M, Nüssler V, Wilmanns W.

Leukemia. 1999 Nov;13(11):1873-80.

8.

Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines.

Nuessler V, Stötzer O, Gullis E, Pelka-Fleischer R, Pogrebniak A, Gieseler F, Wilmanns W.

Leukemia. 1999 Nov;13(11):1864-72.

9.

GM-CSF stimulates proliferation of clonal leukemic bone marrow cells in acute myeloid leukemia (AML) in vitro.

Schmetzer HM, Gerhartz HH, Wilmanns W.

Ann Hematol. 1999 Oct;78(10):449-55.

PMID:
10550555
10.

Value of human chorionic gonadotropin compared to CEA in discriminating benign from malignant effusions.

Lamerz R, Stoetzer OJ, Mezger J, Brandt A, Darsow M, Wilmanns W.

Anticancer Res. 1999 Jul-Aug;19(4A):2421-5.

PMID:
10470169
11.

Human parvovirus B19-associated disease in bone marrow transplantation.

Schleuning M, Jäger G, Holler E, Hill W, Thomssen C, Denzlinger C, Lorenz T, Ledderose G, Wilmanns W, Kolb HJ.

Infection. 1999 Mar-Apr;27(2):114-7.

PMID:
10219641
12.

Cloning and characterization of bone marrow cells from patients with acute lymphoid leukemia (ALL) in agar cultures.

Schmetzer H, Müller C, Wilmanns W, Gerhartz H.

Haematologia (Budap). 1998;29(3):195-205.

PMID:
10069445
13.
14.

Tumor-growth inhibition with bispecific antibody fragments in a syngeneic mouse melanoma model: the role of targeted T-cell co-stimulation via CD28.

Grosse-Hovest L, Brandl M, Dohlsten M, Kalland T, Wilmanns W, Jung G.

Int J Cancer. 1999 Jan 5;80(1):138-44.

15.

In vitro efficacy of known P-glycoprotein modulators compared to droloxifene E and Z: studies on a human T-cell leukemia cell line and their resistant variants.

Nüssler V, Pelka-Fleisc R, Gieseler F, Hasmann M, Löser R, Gullis E, Stötzer O, Zwierzina H, Wilmanns W.

Leuk Lymphoma. 1998 Nov;31(5-6):589-97.

PMID:
9922050
16.

Cytokines in GvH and GvL.

Holler E, Kolb HJ, Eissner G, Wilmanns W.

Bone Marrow Transplant. 1998 Dec;22 Suppl 4:S3-6. Review. No abstract available.

PMID:
9916621
17.

Release of prostaglandin D2 by murine mast cells: importance of metabolite formation for antiproliferative activity.

Haberl C, Hültner L, Flügel A, Falk M, Geuenich S, Wilmanns W, Denzlinger C.

Mediators Inflamm. 1998;7(2):79-84.

18.

Non-invasive temperature mapping using MRI: comparison of two methods based on chemical shift and T1-relaxation.

Bertsch F, Mattner J, Stehling MK, Müller-Lisse U, Peller M, Loeffler R, Weber J, Messmer K, Wilmanns W, Issels R, Reiser M.

Magn Reson Imaging. 1998 May;16(4):393-404.

PMID:
9665550
19.

Regulation of deoxycytidine kinase by deoxycytidine and deoxycytidine 5' triphosphate in whole leukemia and tumor cells.

Heinemann V, Schulz L, Issels RD, Wilmanns W.

Adv Exp Med Biol. 1998;431:249-53. No abstract available.

PMID:
9598069
20.

Induction of leukotriene production by bleomycin and asparaginase in mast cells in vitro and in patients in vivo.

Geuenich S, Haberl C, Egger D, Kaspers U, Hültner L, Wilmanns W, Denzlinger C.

Biochem Pharmacol. 1998 Feb 15;55(4):447-53.

PMID:
9514079
21.

Functional P-gp expression in multiple myeloma patients at primary diagnosis and relapse or progressive disease.

Nuessler V, Gieseler F, Gullis E, Pelka-Fleischer R, Stötzer O, Zwierzina H, Wilmanns W.

Leukemia. 1997 Dec;11 Suppl 5:S10-4.

PMID:
9436932
22.

Development of myeloma and secondary myelodysplastic syndrome from a common clone.

Schmetzer HM, Mittermüller J, Duell T, Wilmanns W.

Cancer Genet Cytogenet. 1998 Jan 1;100(1):31-5.

PMID:
9406577
23.

Enhanced pulmonary accumulation of liposomal amphotericin B (AmBisome) in acute liver transplant failure.

Heinemann V, Bosse D, Jehn U, Debus A, Wachholz K, Forst H, Wilmanns W.

J Antimicrob Chemother. 1997 Aug;40(2):295-7.

PMID:
9302000
24.

Is serum tumor marker half-life a guide to prognosis in metastatic nonseminomatous germ cell tumors?

Gerl A, Lamerz R, Mann K, Clemm C, Wilmanns W.

Anticancer Res. 1997 Jul-Aug;17(4B):3047-9.

PMID:
9329598
25.

Expression and functional activity of P-glycoprotein in adult acute myelogenous leukemia patients.

Nuessler V, Gullis E, Pelka-Fleischer R, del Valle F, Diem H, Beyerlein S, Zwierzina H, Wilmanns W.

Ann Hematol. 1997 Jul-Aug;75(1-2):17-26.

PMID:
9322679
26.

Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients.

Heinemann V, Bosse D, Jehn U, Kähny B, Wachholz K, Debus A, Scholz P, Kolb HJ, Wilmanns W.

Antimicrob Agents Chemother. 1997 Jun;41(6):1275-80.

27.

Clonality analysis as a tool to study the biology and response to therapy in myelodysplastic syndromes.

Schmetzer HM, Poleck B, Mittermüller J, Duell T, Wilmanns W, Gerhartz HH.

Leukemia. 1997 May;11(5):660-6.

28.

Effects of progesterone and leukotriene receptor antagonists in experimental models of P-glycoprotein-related resistance.

Nuessler V, Pelka-Fleischer R, Zwierzina H, Wilmanns W, Denzlinger C.

Eur J Med Res. 1997 Apr 21;2(4):159-64.

PMID:
9110922
29.

Inflammatory reactions induced by pretransplant conditioning--an alternative target for modulation of acute GvHD and complications following allogeneic bone marrow transplantation?

Holler E, Ertl B, Hintermeier-Knabe R, Roncarolo MG, Eissner G, Mayer F, Fraunberger P, Behrends U, Pfannes W, Kolb HJ, Wilmanns W.

Leuk Lymphoma. 1997 Apr;25(3-4):217-24. Review.

PMID:
9168432
30.

Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor.

Engelhard M, Brittinger G, Huhn D, Gerhartz HH, Meusers P, Siegert W, Thiel E, Wilmanns W, Aydemir U, Bierwolf S, Griesser H, Tiemann M, Lennert K.

Blood. 1997 Apr 1;89(7):2291-7.

PMID:
9116271
31.

Chronic myeloid leukemia associated hypereosinophilic syndrome with a clonal t(4;7)(q11;q32).

Duell T, Mittermüller J, Schmetzer HM, Kolb HJ, Wilmanns W.

Cancer Genet Cytogenet. 1997 Apr;94(2):91-4.

PMID:
9109934
32.

Serum pharmacology of amphotericin B applied in lipid emulsions.

Heinemann V, Kähny B, Jehn U, Mühlbayer D, Debus A, Wachholz K, Bosse D, Kolb HJ, Wilmanns W.

Antimicrob Agents Chemother. 1997 Apr;41(4):728-32.

33.

Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation.

Salat C, Holler E, Kolb HJ, Reinhardt B, Pihusch R, Wilmanns W, Hiller E.

Blood. 1997 Mar 15;89(6):2184-8.

PMID:
9058743
34.

Phase I and pharmacokinetic study of the P-glycoprotein modulator dexniguldipine-HCL.

Nuessler V, Scheulen ME, Oberneder R, Kriegmair M, Goebel KJ, Rathgeb F, Wurst W, Zech K, Wilmanns W.

Eur J Med Res. 1997 Feb 21;2(2):55-61.

PMID:
9085015
35.

Adoptive immunotherapy in canine chimeras.

Kolb HJ, Günther W, Schumm M, Holler E, Wilmanns W, Thierfelder S.

Transplantation. 1997 Feb 15;63(3):430-6.

PMID:
9039935
36.

Idarubicin monotherapy in multiply pretreated leukemia patients: response in relation to P-glycoprotein expression.

Nüssler V, Gieseler F, Zwierzina H, Gullis E, Pelka-Fleischer R, Diem H, Abenhardt W, Schmitt R, Langenmayer I, Wohlrab A, Kolb HJ, Wilmanns W.

Ann Hematol. 1997 Feb;74(2):57-64.

PMID:
9063374
37.

Effect of GM-CSF, 1, 25-Dihydroxycholecalciferol (Vit.D) and All-Trans-Retinoic Acid (ATRA) on the Proliferation and Differentiation of MDS-Bone Marrow (BM)-Cells In Vitro.

Schmetzer HM, Rapp L, Wilmanns W, Gerhartz HH.

Hematology. 1997;2(1):11-9. doi: 10.1080/10245332.1997.11746315.

PMID:
27406722
38.

Late relapse of germ cell tumors after cisplatin-based chemotherapy.

Gerl A, Clemm C, Schmeller N, Hentrich M, Lamerz R, Wilmanns W.

Ann Oncol. 1997 Jan;8(1):41-7. Review.

PMID:
9093706
39.

Advances in the management of metastatic non-seminomatous germ cell tumours during the cisplatin era: a single-institution experience.

Gerl A, Clemm C, Schmeller N, Hartenstein R, Lamerz R, Wilmanns W.

Br J Cancer. 1996 Oct;74(8):1280-5.

40.

Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors?

Gerl A, Lamerz R, Clemm C, Mann K, Hartenstein R, Wilmanns W.

Clin Cancer Res. 1996 Sep;2(9):1565-70.

41.

[54-year-old, severely ill patient with diffuse pain syndrome, peripheral facial paralysis and progressive tetraparesis].

Duell T, Schalhorn A, Pötscher C, Haberl C, Beykirch M, Pfister W, Wilmanns W.

Internist (Berl). 1996 Aug;37(8):839-43. German. No abstract available.

PMID:
8964676
43.

P-glycoprotein expression in patients with acute leukemia-clinical relevance.

Nüssler V, Pelka-Fleischer R, Zwierzina H, Nerl C, Beckert B, Gieseler F, Diem H, Ledderose G, Gullis E, Sauer H, Wilmanns W.

Leukemia. 1996 Jul;10 Suppl 3:S23-S31.

PMID:
8656697
44.

Association of bcl-2, bax, bcl-xL and interleukin-1 beta-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia.

Stoetzer OJ, Nüssler V, Darsow M, Gullis E, Pelka-Fleischer R, Scheel U, Wilmanns W.

Leukemia. 1996 Jul;10 Suppl 3:S18-S22.

PMID:
8656695
45.

[Medical differential diagnosis of backache].

Gerl A, Wilmanns W.

Dtsch Med Wochenschr. 1996 Apr 12;121(15):499-500. German. No abstract available.

PMID:
8605845
46.

Autoantibodies against p53 are not increased in human ascites and pleural effusions.

Munker R, Stötzer O, Darsow M, Classen S, Lebeau A, Wilmanns W.

Cancer Immunol Immunother. 1996 Mar;42(3):200-1.

PMID:
8640849
47.

Cisplatin-based chemotherapy of primary extragonadal germ cell tumors. A single institution experience.

Gerl A, Clemm C, Lamerz R, Wilmanns W.

Cancer. 1996 Feb 1;77(3):526-32.

PMID:
8630961
48.
49.

Myocardial-infarction after adjuvant chemotherapy for resected stage-ii nonseminomatous testicular cancer.

Gerl A, Weigl P, Gassel W, Wilmanns W.

Oncol Rep. 1995 Nov;2(6):1097-9.

PMID:
21597861
50.

[Young man with swelling of the left side of the neck and right testis].

Jakob AR, Kühl M, Wilmanns W, Schalhorn A.

Internist (Berl). 1995 Nov;36(11):1080-4. German. No abstract available.

PMID:
8543445

Supplemental Content

Loading ...
Support Center